CNS PharmaceuticalsCNS PharmaceuticalsCNS Pharmaceuticals
  • Brain
    • Glioblastoma
    • Anthracyclines
    • Blood Brain Barrier
  • Technology
    • Berubicin
    • Pipeline
  • Team
    • Management
    • Board
  • About Us
  • Contact
  • Investors
  • Sign Up

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Analyst Coverage
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts

CNS Pharmaceuticals Signs Agreement with WPD Pharmaceuticals to Develop Drug Candidates for a Range of Viruses including Coronavirus for International Markets

Mar 23, 2020 8:00am EDT

CNS Pharmaceuticals Announces Business Highlights and 2019 Fourth Quarter Financial Results

Mar 12, 2020 4:05pm EDT

CNS Pharmaceuticals to Report Fourth Quarter 2019 Financial Results on March 12, 2020

Mar 05, 2020 4:05pm EST

CNS Pharmaceuticals Announces Brain Cancer Patient from Berubicin Phase 1 Trial Remains Cancer Free

Mar 03, 2020 8:00am EST

CNS Pharmaceuticals to Ring Nasdaq Stock Market Opening Bell on March 3

Feb 27, 2020 8:00am EST

CNS Pharmaceuticals Announces Collaboration with European Partner to Expand Clinical Trials to Pediatric Brain Tumors

Feb 11, 2020 8:00am EST

CNS Pharmaceuticals Announces Completion of GMP Manufacturing

Feb 04, 2020 8:00am EST

CNS Pharmaceuticals Completes Pilot Manufacturing Steps Pursuant to FDA Pre-IND Guidance

Jan 28, 2020 8:00am EST

CNS Pharmaceuticals Announces Contract with International GMP Manufacturer for Production of Berubicin

Jan 14, 2020 8:00am EST

CNS Pharmaceuticals Licenses DNA-Binding Agent from MD Anderson, Doubling its Drug Pipeline

Jan 13, 2020 8:00am EST
RSS
  • Prev
    • 1...
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    Next
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed

    © 2023 CNS Pharmaceuticals. All Rights Reserved, CNS Pharma

    • Brain
      • Glioblastoma
      • Anthracyclines
      • Blood Brain Barrier
    • Technology
      • Berubicin
      • Pipeline
    • Team
      • Management
      • Board
    • About Us
    • Contact
    • Investors
    • Sign Up